October 2, 20250 citations
Supplementary Figure S3 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
View Full Paper
Key Points
- Distinct biological clusters identified from gene expression profiling, impacting prognosis significantly.
- Analysis of gene markers like KRT5 and CD44 reveals potential for improved outcomes after neoadjuvant therapy.
- Method derived from gene expression scores in cystectomy samples, highlighting the role of transcripts in treatment response.
- Findings suggest transcriptomic profiles may guide future treatment approaches and patient management in bladder cancer.
Abstract
Figure S3. Defining novel biological clusters using gene expression profiling in radical cystectomy samples previously treated with neoadjuvant atezolizumab. Gene marker expression scores among ABACUS CC1-4 for (A) KRT5, (B) KRT14, (C) CD44, (D) PPARG, (E) GATA3, (F) KRT20, (G) MYH11, (H) DES, and (I) C7.
Cite This Study
Jong et al. (2025) studied this question.